| [1] |
FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352. DOI: 10.1016/j.jhep.2007.11.011. |
| [2] |
ATTAR BM. CON: All patients with immune-tolerated hepatitis B virus do not need to be treated[J]. Clin Liver Dis (Hoboken), 2020, 15(1): 25-30. DOI: 10.1002/cld.893. |
| [3] |
CHAN HL, CHAN CK, HUI AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA[J]. Gastroenterology, 2014, 146(5): 1240-1248. DOI: 10.1053/j.gastro.2014.01.044. |
| [4] |
WU ZX, CHEN FS, ZHOU XL, et al. Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: An open-label, randomized, controlled study[J]. Eur J Gastroenterol Hepatol, 2019, 31(7): 832-835. DOI: 10.1097/MEG.0000000000001345. |
| [5] |
FELD JJ, TERRAULT NA, LIN HS, et al. Entecavir and peginterferon alfa-2a in adults with hepatitis B e antigen-positive immune-tolerant chronic hepatitis B virus infection[J]. Hepatology, 2019, 69(6): 2338-2348. DOI: 10.1002/hep.30417. |
| [6] |
HUI CK, LEUNG N, YUEN ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J]. Hepatology, 2007, 46(2): 395-401. DOI: 10.1002/hep.21724. |
| [7] |
LEE HW, KIM EH, LEE J, et al. Natural history of untreated HBeAg-positive chronic HBV infection with persistently elevated HBV DNA but normal alanine aminotransferase[J]. Clin Transl Gastroenterol, 2020, 11(3): e00140. DOI: 10.14309/ctg.0000000000000140. |
| [8] |
CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65. |
| [9] |
KIM GA, LIM YS, HAN S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2018, 67(5): 945-952. DOI: 10.1136/gutjnl-2017-314904. |
| [10] |
ZHANG N, ZHAO YY, OU WN, et al. Analysis on the liver histology of 229 chronic hepatitis B patients with normal or slightly elevated alanine aminotransferase level[J/CD]. Chin J Exp Clin Infect Dis(Electronic Edition), 2014, 8(1): 14-17. DOI: 10.3877/cma.j.issn.1674-1358.2014.01.004. |
| [11] |
LIAW YF, BRUNETTO MR, HADZIYANNIS S. The natural history of chronic HBV infection and geographical differences[J]. Antivir Ther, 2010, 15(Suppl 3): 25-33. DOI: 10.3851/IMP1621. |
| [12] |
ANDREANI T, SERFATY L, MOHAND D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome[J]. Clin Gastroenterol Hepatol, 2007, 5(5): 636-641. DOI: 10.1016/j.cgh.2007.01.005. |
DownLoad: